Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Farmers Insurance
US Army
QuintilesIMS
Citi
UBS
Healthtrust
Deloitte
Harvard Business School

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021251

« Back to Dashboard

NDA 021251 describes KALETRA, which is a drug marketed by Abbvie and is included in three NDAs. It is available from nine suppliers. There are sixteen patents protecting this drug and two Paragraph IV challenges. Additional details are available on the KALETRA profile page.

The generic ingredient in KALETRA is lopinavir; ritonavir. There are thirteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the lopinavir; ritonavir profile page.
Summary for 021251
Tradename:KALETRA
Applicant:Abbvie
Ingredient:lopinavir; ritonavir
Patents:2
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 021251
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
KALETRA lopinavir; ritonavir SOLUTION;ORAL 021251 NDA AbbVie Inc. 0074-3956 N 0074-3956-46

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;ORALStrength80MG/ML;20MG/ML
Approval Date:Sep 15, 2000TE:AARLD:Yes
Patent:➤ Sign UpPatent Expiration:May 28, 2022Product Flag?Substance Flag?Delist Request?Y
Patent:➤ Sign UpPatent Expiration:Nov 28, 2021Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 021251

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie KALETRA lopinavir; ritonavir SOLUTION;ORAL 021251-001 Sep 15, 2000 ➤ Sign Up ➤ Sign Up
Abbvie KALETRA lopinavir; ritonavir SOLUTION;ORAL 021251-001 Sep 15, 2000 ➤ Sign Up ➤ Sign Up
Abbvie KALETRA lopinavir; ritonavir SOLUTION;ORAL 021251-001 Sep 15, 2000 ➤ Sign Up ➤ Sign Up
Abbvie KALETRA lopinavir; ritonavir SOLUTION;ORAL 021251-001 Sep 15, 2000 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Farmers Insurance
Fuji
Cerilliant
US Army
Argus Health
Chubb
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.